非アルコール性脂肪性肝炎(Non-Alcoholic Steatohepatitis)：世界の治験レビュー（2015年上半期版）...市場調査レポートについてご紹介

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Non-Alcoholic Steatohepatitis 7
Report Guidance 7
Clinical Trials by Region 8
Clinical Trials and Average Enrollment by Country 9
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 11
Top Five Countries Contributing to Clinical Trials in Europe 12
Top Countries Contributing to Clinical Trials in North America 13
Top Countries Contributing to Clinical Trials in Middle East and Africa 14
Top Five Countries Contributing to Clinical Trials in Central and South America 15
Clinical Trials by G7 Countries: Proportion of Non-Alcoholic Steatohepatitis to Gastrointestinal Clinical Trials 16
Clinical Trials by Phase in G7 Countries 17
Clinical Trials in G7 Countries by Trial Status 18
Clinical Trials by E7 Countries: Proportion of Non-Alcoholic Steatohepatitis to Gastrointestinal Clinical Trials 19
Clinical Trials by Phase in E7 Countries 20
Clinical Trials in E7 Countries by Trial Status 21
Clinical Trials by Phase 22
In Progress Trials by Phase 23
Clinical Trials by Trial Status 24
Clinical Trials by End Point Status 25
Unaccomplished Trials of Non-Alcoholic Steatohepatitis 26
Subjects Recruited Over a Period of Time 28
Clinical Trials by Sponsor Type 29
Prominent Sponsors 30
Top Companies Participating in Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials 31
Prominent Drugs 32
Latest Clinical Trials News on Non-Alcoholic Steatohepatitis 33
May 04, 2015: Islet Sciences Publishes Data Supporting Remogliflozin Etabonate as a Potential Treatment for NAFLD and NASH 33
Apr 23, 2015: Diabetes drug shows promise in the treatment of non-alcoholic steatohepatitis 33
Apr 23, 2015: Intercept Announces New FLINT Trial Data Showing OCA Treatment Increases Fibrosis Resolution and Cirrhosis Prevention in High-Risk NASH Patients 34
Apr 23, 2015: Conatus Clinical Results at EASL Meeting Support Emricasan Registration Pathway in NASH 35
Apr 21, 2015: Nimbus Therapeutics Announces Initiation of Clinical Studies for ACC Inhibitor 36
Apr 21, 2015: Upcoming AACR and EASL poster presentations support Nimbus’ novel, liver-directed approach to allosteric ACC inhibition across liver disease spectrum, including NASH and HCC 36
Apr 20, 2015: NGM Biopharmaceuticals to Present New Data on NGM282 at the European Association for the Study of the Liver International Liver Congress 2015 37
Apr 08, 2015: Tobira Therapeutics Highlights Presentations at The International Liver Congress 2015 37
Apr 08, 2015: Conatus Pharmaceuticals to Present Three Emricasan Clinical Results Posters at EASL Meeting 38
Mar 30, 2015: DURECT Announces Initiation of DUR-928 Multi-Dose Phase 1 Study 38
Mar 26, 2015: Conatus Announces Successful Top-Line Results From NAFLD/NASH Clinical Trial of Emricasan 39
Mar 20, 2015: Intercept Announces New Data Analyses From FLINT Trial of Obeticholic Acid in NASH 40
Mar 18, 2015: Metabolic Solutions Development Company Highlights Plans for MSDC-0602 in NASH and Polycystic Kidney Disease 41
Mar 12, 2015: Galectin Therapeutics Engages PPD to Conduct GR-MD-02 Phase 2 Trial in NASH, Submits Special Protocol Assessment to FDA 41
Mar 09, 2015: Islet Sciences COO to Present at EASL: Remogliflozin Etabonate as Novel Treatment for Non-alcoholic Steatohepatitis (NASH) 42
Mar 09, 2015: Galmed Pharmaceuticals Announces the Beginning of Enrollment in its Phase IIb ARREST Trial for the Treatment of NASH, as well as the Expansion of the Study to the United States 42
Feb 25, 2015: MediciNova’s MN-001 (tipelukast) NASH with Advanced Fibrosis Abstract Accepted for Presentation at the AASLD and Industry Colloquium: Novel Targets and Therapies in Liver Disease in Durham, North Carolina 43
Feb 24, 2015: Galectin Therapeutics Announces Details of the Design of Its Phase 2 Program With GR-MD-02 43
Clinical Trial Profiles 45
Clinical Trial Overview of Top Companies 45
Genextra S.p.a. 45
Clinical Trial Overview of Genextra S.p.a. 45
Genfit SA 46
Clinical Trial Overview of Genfit SA 46
Cempra, Inc. 47
Clinical Trial Overview of Cempra, Inc. 47
Raptor Pharmaceuticals Corp. 48
Clinical Trial Overview of Raptor Pharmaceuticals Corp. 48
Nimbus Therapeutics, LLC 49
Clinical Trial Overview of Nimbus Therapeutics, LLC 49
Immuron Limited 50
Clinical Trial Overview of Immuron Limited 50
Gilead Sciences, Inc. 51
Clinical Trial Overview of Gilead Sciences, Inc. 51
Galmed International Ltd. 52
Clinical Trial Overview of Galmed International Ltd. 52
Galectin Therapeutics, Inc. 53
Clinical Trial Overview of Galectin Therapeutics, Inc. 53
DURECT Corporation 54
Clinical Trial Overview of DURECT Corporation 54
Clinical Trial Overview of Top Institutes / Government 55
The National Institute of Diabetes and Digestive and Kidney Diseases 55
Clinical Trial Overview of The National Institute of Diabetes and Digestive and Kidney Diseases 55
Tehran University of Medical Sciences 56
Clinical Trial Overview of Tehran University of Medical Sciences 56
University of California, San Diego 57
Clinical Trial Overview of University of California, San Diego 57
National Nutrition and Food Technology Research Institute 58
Clinical Trial Overview of National Nutrition and Food Technology Research Institute 58
Yokohama City University 59
Clinical Trial Overview of Yokohama City University 59
Bambino Gesu Hospital and Research Institute 60
Clinical Trial Overview of Bambino Gesu Hospital and Research Institute 60
Ghent University Hospital 61
Clinical Trial Overview of Ghent University Hospital 61
Gunma Liver Study Group 62
Clinical Trial Overview of Gunma Liver Study Group 62
Hadassah Medical Organization 63
Clinical Trial Overview of Hadassah Medical Organization 63
Hiroshima University Hospital 64
Clinical Trial Overview of Hiroshima University Hospital 64
Five Key Clinical Profiles 65
Appendix 91
Abbreviations 91
Definitions 91
Research Methodology 92
Secondary Research 92
About GlobalData 93
Contact Us 93
Disclaimer 93
Source 93